PRTG PORTAGE BIOTECH INC

Portage Biotech to Present at Upcoming Investor Conferences

Portage Biotech to Present at Upcoming Investor Conferences

WESTPORT, Conn., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced that the Company’s management team will be presenting at the following upcoming investor conferences:

H.C. Wainwright 24th Annual Global Investment Conference
Date / Time:September 13, 2022 at 9:30am ET
Format:Company Presentation



Cantor Fitzgerald’s Oncology, Hematology, & HemeOnc Conference
Date / Time:September 28, 2022 at 1:45pm ET
Format:Panel Presentation: Trends and Challenges in Immuno-Oncology

The Portage management team will participate in one-on-one investor meetings during each of these events. Investors interested in meeting with Portage at the conferences should contact their respective event representative.

About Portage Biotech Inc.

Portage is a clinical-stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive cancers. Portage’s access to next-generation technologies coupled with a deep understanding of biological mechanisms enables the identification of the most promising clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. Portage’s portfolio consists of six diverse platforms, with lead programs including invariant natural killer T cell (iNKT agonists) and a suite of treatments targeting the adenosine pathway. Additional programs leverage delivery by intratumorals, nanoparticles, liposomes, aptamers, and virus-like particles. Within these six platforms, Portage has 14 products currently in development with multiple clinical readouts expected through the end of 2023. For more information, please visit , follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations

Chuck Padala

Media Relations

Gwendolyn Schanker



EN
08/09/2022

Underlying

PRTGPORTAGE BIOTECH INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PORTAGE BIOTECH INC

 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025 DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands, with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal year ended March 31, 2025. Financial Results from Year Ended March 31, 2025 The Company incurred a net loss of approximately $6.8 million during the fiscal year ended Marc...

July 25, 2025 1 EN
 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing ...

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. About Portage BiotechPortage Biotech is a clinical-stage i...

June 25, 2025 1 EN
 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech and Compedica Stock-for-Stock Exchange

Portage Biotech and Compedica Stock-for-Stock Exchange DOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”) announce that on June 5, 2025 Portage and Compedica Holdings Limited, a company formed under the laws of the Isle of Man (“Compedica”) entered a mutual Subscription Agreement (“Subscription Agreement”). Pursuant to the Subscription Agreement, Portage issued 625,000 ordinary shares at a per share price of $8.00 in exchange for 1,165,501 shares of Co...

June 9, 2025 1 EN
 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelio...

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor. Dr. Luciano Mutti of the Department of Applied Clinical Sciences and Biotechnology at the University of L'Aquila, Italy, an internationally recognized expert in mesothelioma, will be presenting the data at the American Association for C...

April 28, 2025 1 EN
 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech Reports Promising Preclinical Results in Mesothelioma ...

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibody DOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo I...

March 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch